Bernard A. Fox Phd Email & Phone Number

Portland, Us

UbiVac is a clinical stage immuno-oncology and cancer target discovery company engaged in the research, development and testing of therapeutic immunotherapy strategies to combat cancer. UbiVac currently has two platforms under development: 1) DPV (Dribbles Platform Vaccine) - DC-targeted microvesicles containing cancer’s dark matter /alternative cancer neoantigens + more than 300 shared cancer antigens, including "NCI-prioritized" cancer antigens, five TLR/NOD agonists and 15 DAMPs/molecular chaperones, 2) Ubiquitin Platform Vaccine (UPV). UbiVac's lead product, DPV-001, has completed an NCI-funded, randomized multi-center phase I/II clinical trial (NCT01909752) for adjuvant treatment of patients with definitively treated non-small cell lung cancer (NSCLC). Results showed induction of anti-cancer immunity in all patients and were reported in abstract format at the 2017 ASCO and SITC meetings. UbiVac also sponsored a pilot study of DPV-001 in men with advanced prostate cancer (NCT02234921). A clinical trial of DPV-001 + anti-PD-1 +/-anti-OX40 for patients with advanced triple negative breast cancer, based on strong preclinical studies (Scientific Reports | 6:37558), opened but was impacted by COVID and BMS decision to stop development of anti-OX40. In collaboration with Incyte, currently enrolling patients with advanced/metastatic head and neck cancer (HNSCC) on a trial of combination immunotherapy including DPV-001 + anti-PD-1. Analysis of the first 18 patients presented at AACR reported more than a tripling of the objective response rate in PD-1 naive patients (56% vs the 16% on label) and a 33% response rate in PD-1 experienced/refractory patients. Founded in Portland, OR in 2005 as a spin-out of the Robert W. Franz Cancer Center within the Earle A. Chiles Research Institute, at Providence Portland Medical Center, UbiVac continues to build upon the groundbreaking research being developed in the region.www.UbiVac.com

Portland, Or, Us

Dr. Fox's goals are to: 1) Develop effective immunotherapies that eliminate tumors in mice, 2) Translate these into patients with cancer, 3) Train next generation of translational investigators.The preclinical group (Dr. Shawn Jensen, David Messenheimer, Tyler Hulett and Zip Feng) use animal models to develop new strategies to augment therapeutic immunotherapy and also defines the mechanisms of T cell-mediated tumor elimination and tumor escape. The translational group (Dr. Sachin Puri, Dr. Christopher Paustian, Tyler Hulett and Zip Feng) transfer these developments into clinical trials, monitor patient’s anti-tumor immune response and develops hypotheses that are returned to the preclinical group for testing in animal models.Current efforts are directed at understanding and characterizing the cellular and humoral anti-tumor immune response. Our group has collaborations with Hong-Ming Hu's lab (EACRI) that are exploring how using autophagasomes can improve cross-presentation of tumor antigens and augment antitumor immunity. We also have a collaboration with Ann Hill’s lab that exploits their observations that vaccination with CMV vectors results in a high percentage of T cells recognizing the CMV vector. By placing tumor/tumor-associated antigens in CMV vectors we are evaluating if this strategy has therapeutic potential. Collaborations with Dominik Ruttinger, Hauke Winter and Natasja van den Engle at the LMU, Munich, Germany are translating discoveries in preclinical models into patients with non small cell lung cancer (NSCLC) and gastric cancer. Collaborations with the FDA are using micro arrays to characterize genes that are overexpressed in circulating tumor cells (CTC) with hopes of using this information to develop the next generation immunotherapies and aid in immunological monitoring and biomarker development.http://oregon.providence.org/our-services/r/robert-w-franz-cancer-research-center/

Portland, Oregon, Us

Dr. Fox is a member of the OHSU graduate faculty with an appointment in the Molecular Microbiology and Immunology Department. He has been a member of the OHSU Cancer Center since 1994, now the Knight Cancer Institute. Dr. Fox trains PhD and MD, PHD, candidates as well as postdoctoral fellows.

Portland, Oregon, Us

The Oregon Bioscience Association provides a unified voice for the Oregon bioscience community by:• Representing the bioscience research-to-commercialization process• Accelerating the growth of the biosciences industry in all parts of Oregon• Enhancing the state's bioscience business and research climate• Helping attract and retain bioscience talent and companies.• Vigorously working to improve the quality of the bioscience workforce• Partnering with government at all levels to achieve its goals

In November, 2017, the World Immunotherapy Council will have an International meeting of their member societies prior to the annual meeting of the Society for Immunotherapy of Cancer (SITC).

Milwaukee, Wisconsin, Us

Newberg, Or, Us

Promote Oregon wines at International cancer immunotherapy conferences

Silver Spring, Md, Us

Member, US FDA Advisory Committee - CBER: Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC)

Milwaukee, Wisconsin, Us

The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals. Recent advances in immunology and biology have opened up new horizons in the field of cancer therapy, with an upsurge in the integration of new biologic agents into clinical practice.With several high-caliber scientific meetings with a focus on clinical and translational aspects of biologic approaches to cancer treatment and numerous networking opportunities unique to this organization, the Society for Immunotherapy of Cancer (SITC) has developed into the premier destination for interaction and innovation in the cancer biologics community.The goals of SITC are directed towards the rapid dissemination of information in these areas to expedite the safe transfer of both basic and applied research to the clinical setting.Core PurposeTo improve cancer patient outcomes by advancing the science, development and application of biological therapy/immunotherapy.Core ValuesInteraction/Integration - exchange of information and education among basic and translational researchers, clinicians, and young investigators; societies and groups sharing the vision and core values of SITCInnovation - challenge the thinking and seek the best research in the development of biological therapy/immunotherapyTranslation - promote the application and understanding of biological therapy/immunotherapyLeadership - define what is new and important and effectively communicate it to all relevant stakeholders

The Society for Immunotherapy of Cancer (SITC), formerly the International Society for Biological Therapy of Cancer (iSBTc).The goals of SITC are directed towards the rapid dissemination of information in these areas to expedite the safe transfer of both basic and applied research to the clinical setting.

München, Bavaria, De

Ann Arbor, Mi, Us

Part of team, led by Drs. Alfred Chang and Suyu Shu, that pioneered autologous tumor vaccination to generate T cells for adoptive immunotherapy of cancer (PMID: 9053507). Worked with Drs. Gary J. Nabel and Alfred Chang on the first in vivo gene therapy. This trial used lipofection to deliver plasmid DNA into cancer lesions. Studies demonstrated expression of transferred gene and effect of treatment (PMID: 8248244, PMID: 8155772, PMID: 7728301)

Bethesda, Md, Us

Bethesda, Md, Us

Staff Fellow - Senior Staff Fellow, Cancer Immunotherapy

Phd, Regulatory Cell Biology And Biophysics

Ms, Immunology

Bachelor Of Science - Bs, Cell Biology, With A Minor In The History Of Renaissance And The Reformation

Education record

Education record